Proactiveinvestors Australia Anatara Lifesciences Ltd https://www.proactiveinvestors.com.au Proactiveinvestors Australia Anatara Lifesciences Ltd RSS feed en Sun, 24 Feb 2019 12:12:34 +1100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - Anatara Lifesciences to outline its new strategy in human health at Proactive CEO Sessions ]]> https://www.proactiveinvestors.com.au/companies/news/214040/anatara-lifesciences-to-outline-its-new-strategy-in-human-health-at-proactive-ceo-sessions-214040.html Anatara Lifesciences Ltd (ASX:ANR) is focused on its new business strategy in human health, and in particular the development and partnering of its GaRP dietary supplement.

The company will outline its progress and strategy during this month’s Proactive CEO Sessions. Chief executive officer Steven Lydeamore will present to investors at the Melbourne CEO Session on Tuesday, February 19.

Lydeamore has 26 years’ international experience in the pharmaceutical industry, working in Australia, USA and Canada. He brings a strong track record of successfully commercialising products on a global scale.

@AnataraANR $ANR releases Appendix 4C quarterly report for Dec 2018 quarter #guthealth #detach #GaRP #randdtax #CEO #IBS #IBD #humanhealth https://t.co/Ev6OzKAbxm pic.twitter.com/Zll2g1aaX6

— Anatara Lifesciences (@AnataraANR) January 30, 2019

Anatara’s product candidate GaRP is an evidence-based dietary supplement aimed at restoring and maintaining gut health. It is well advanced in proof of concept studies.

With foundations built on strong and successful science, GaRP has been designed to address the primary underlying factors associated with gastrointestinal disorders such as Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD).

 

Animal health to human health

In October 2018, Anatara had received approval from the Australian Pesticides and Veterinary Medicines Authority (APVMA) for its animal health product licensed to Zoetis Inc.

The animal health product Detach has the approved label, “To aid in the control of scour and has positive health benefits in weaned piglets from 3 weeks of age and help increase survivability of scouring pre-weaning piglets”.

Following the successful licencing of its first product to Zoetis Inc, Anatara is now focused on building a pipeline of human gastrointestinal health products.

Register for the CEO Sessions today to find out more.

Melbourne details, Tuesday, February 19, 2019

Also featuring at the event will be Kazia Therapeutics Ltd (ASX:KZA), Peninsula Energy Ltd (ASX:PEN) and AdAlta Ltd (ASX:1AD).

]]>
Wed, 06 Feb 2019 12:35:00 +1100 https://www.proactiveinvestors.com.au/companies/news/214040/anatara-lifesciences-to-outline-its-new-strategy-in-human-health-at-proactive-ceo-sessions-214040.html
<![CDATA[News - Anatara Lifesciences to reveal details on animal health company ]]> https://www.proactiveinvestors.com.au/companies/news/182568/anatara-lifesciences-to-reveal-details-on-animal-health-company-182568.html Anatara Lifesciences Ltd (ASX:ANR) has been granted a trading halt by the ASX, pending the Evaluation and License Option Agreement with animal health company Zoetis Inc. for Detach™.

Detach™ has the potential to play a part as an alternative to traditional antibiotics to control infections in farm animals, as public health officials worldwide seek strategies to combat antimicrobial resistance.

The halt will remain in place until the opening of trade on Monday 21st August 2017, or earlier if an announcement is made to the market.

]]>
Thu, 17 Aug 2017 11:37:00 +1000 https://www.proactiveinvestors.com.au/companies/news/182568/anatara-lifesciences-to-reveal-details-on-animal-health-company-182568.html
<![CDATA[News - Anatara Lifesciences Ltd's Dr Paul Schober outlines Detach™ at Spotlight CEO Session ]]> https://www.proactiveinvestors.com.au/companies/news/165227/anatara-lifesciences-ltds-dr-paul-schober-outlines-detach-at-spotlight-ceo-session-70268.html Anatara Lifesciences Ltd (ASX:ANR) is developing therapeutics for gastrointestinal diseases such in pigs and humans.

Its lead product Detach™ is a natural therapy that prevents and treats gastrointestinal diseases, with the company on track to lodge regulatory approvals, with its Australian launch planned for 2017.

This week Dr Paul Schober, CEO, joined the Proactive Spotlight CEO Investor Session in Sydney, outlining the company strategy to investors.

ACCESS THE FULL PRESENTATION HERE

 

Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

]]>
Fri, 05 Aug 2016 14:30:00 +1000 https://www.proactiveinvestors.com.au/companies/news/165227/anatara-lifesciences-ltds-dr-paul-schober-outlines-detach-at-spotlight-ceo-session-70268.html
<![CDATA[News - Anatara Lifesciences Ltd to detail Detach™ at CEO Spotlight Session ]]> https://www.proactiveinvestors.com.au/companies/news/131861/anatara-lifesciences-ltd-to-detail-detach-at-ceo-spotlight-session-131861.html Anatara Lifesciences Ltd (ASX:ANR) is developing therapeutics for gastrointestinal diseases such in pigs and humans.

Its lead product Detach™ is a natural therapy that prevents and treats gastrointestinal diseases, with the company on track to lodge regulatory approvals, with its Australian launch planned for 2017.

Furthermore, unlike antibiotics, Detach™ will not contribute to antimicrobial resistance.

The overuse of antibiotics in production animals is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat.

Anatara signed its first partner deal in January with Zoetis Inc. (NYSE:ZTS), the number one global animal health company.


Find out more from Dr Paul Schober, CEO, at Proactive's Spotlight CEO Sessions in Sydney in August 2016.

REGISTER HERE, CLICK ON LINK: Sydney Investor Sessions, Wednesday, 3rd August


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Thu, 21 Jul 2016 10:10:00 +1000 https://www.proactiveinvestors.com.au/companies/news/131861/anatara-lifesciences-ltd-to-detail-detach-at-ceo-spotlight-session-131861.html
<![CDATA[News - Anatara Lifesciences Ltd delves further into treatment of diarrhoea in pigs ]]> https://www.proactiveinvestors.com.au/companies/news/131860/anatara-lifesciences-ltd-delves-further-into-treatment-of-diarrhoea-in-pigs-69255.html Anatara Lifesciences Ltd (ASX:ANR) has commenced a third field trial to win local registration for Detach, to prevent and treat the incidence of scour (diarrhoea) in pigs.

Anatara’s third Australian field trial is being conducted on a major commercial piggery by enrolling 450 two-day old unweaned piglets.

The objective of this study is to provide detailed safety data on Detach when administered orally to piglets at dose rates higher than the recommended single dose.

Detach is a non-antibiotic, natural therapeutic to prevent and treat diarrhoea, in piglets.

This study is aimed at harmonising the technical requirements for veterinary product registration, and will further support the global rollout of Detach.

Anatara’s current studies will also accomplish the clinical trial requirements to prepare the Dossier for the Australian Pesticides and Veterinary Medicines Authority.

Detach could be on sale in Australia in 2017, with approval for the sale of Detach™ in Australia, opening the way to register it for sale in major Asian markets.

Adding interest, Anatara has entered into an R&D collaboration with the La Trobe University in Melbourne to develop active components within Detach for the treatment of inflammatory diseases in humans and companion animals.

The company had announced a swelling of its cash balance of $14.35 million in April 2016, after shipping Detach to Zoetis Inc. (NYSE:ZTS) under their exclusive global evaluation and licence option agreement.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Thu, 16 Jun 2016 17:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/131860/anatara-lifesciences-ltd-delves-further-into-treatment-of-diarrhoea-in-pigs-69255.html
<![CDATA[News - Anatara Lifesciences’ treatment reduces diarrhoea in piglets during field trial ]]> https://www.proactiveinvestors.com.au/companies/news/131859/anatara-lifesciences-treatment-reduces-diarrhoea-in-piglets-during-field-trial-64548.html Anatara Lifesciences’ (ASX:ANR) Detach non-antibiotic natural therapy has reduced the occurrence of diarrhoea (scour) in piglets during the second Australian field trial.

Detach reduced the number of pigs with scour by 41% and reduced the severity of scour by 45%.   

Positive results have now confirmed in two age groups of piglets; suckers (unweaned) as well as weaner piglets, in two geographical regions.

The data is consistent with earlier registration trials on commercial pig farms and supports Anatara’s plan to re-register and launch Detach in Australia.

It is now focused on completing a third and final field trial.

In August, the company signed a commercial collaboration agreement with Government funded Pork Cooperative Research Centre (Pork CRC).

Pork CRC will provide Anatara with services to locate key clinical trial sites and ongoing test sites, assist with the Australian Pesticides and Veterinary Medicines Authority approval of Detach and promote the results of these trials.

Anatara had $1.5 million in cash and equivalents as at 30th June 2015.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 16 Sep 2015 10:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/131859/anatara-lifesciences-treatment-reduces-diarrhoea-in-piglets-during-field-trial-64548.html
<![CDATA[News - Anatara Lifesciences to grow cash position ]]> https://www.proactiveinvestors.com.au/companies/news/131858/anatara-lifesciences-to-grow-cash-position-63227.html Anatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans.

Anatara’s shares have been a top performer in 2015, last trading at $1, which is more than three times higher than where the company started the year.

The ASX has now granted the company a trading halt to complete a capital raising.

The halt will last until the opening of trade on Friday 3rd July 2015, or earlier if an announcement is made to the market.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 01 Jul 2015 16:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/131858/anatara-lifesciences-to-grow-cash-position-63227.html
<![CDATA[News - Anatara Lifesciences developing non-antibiotic gastrointestinal treatments ]]> https://www.proactiveinvestors.com.au/companies/news/131857/anatara-lifesciences-developing-non-antibiotic-gastrointestinal-treatments-63154.html Anatara Lifesciences (ASX:ANR) is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans with its lead product Detach™ for the prevention and treatment of diarrhoea in weaned pigs now in its second pivotal field trial.

Notably, this therapy addresses concerns around the overuse of antibiotics in animals and their feed.

The second field trial is being conducted in a major commercial piggery and will support Anatara’s application to register Detach™ for sale in Australia with the Australian Pesticides and Veterinary Medicines Authority (APVMA).

Approval for sale of the product in Australia will open the opportunity to quickly register Detach™ for sale in major Asian markets.

A minimum of 560 weaners have been enrolled in this second study with results expected within the third quarter 2015.

The first weaners have been dosed with Detach™ in a placebo controlled, parallel group, randomised and blinded study.

The trial will investigate the ability of Detach™ to reduce the incidence, severity and duration of diarrhoea, otherwise known as scour, compared to placebo.

Anatara has already produced just under 500,000 doses of Detach™ at commercial scale under the code of good manufacturing practice and in line with registration requirements of the APVMA.

It plans to run a third field trial with the site already in advanced planning stage.

The company expects Detach™ to be on sale in 2016 based on the current pace of progress and with trial results supporting existing data.

Launch into a number of Asian markets is targeted to follow shortly after. Planning for the registration of Detach™ in Europe and the USA is also well advanced.

Earlier this month, the company received written confirmation from the U.S. Food and Drug Administration (FDA) that it has been granted a sponsor fee waiver.

This means that Anatara can initiate its INAD application for field studies in the U.S. without having to pay the US$100,000 annual Sponsor User Fee.

Anatara can also commence seeking guidance from the FDA on their likely approach to Detach™ registration.

Separately, the company has received its first refund of $61,000 from 2013 research activities. Future refunds will increase significantly.



Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Fri, 26 Jun 2015 16:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/131857/anatara-lifesciences-developing-non-antibiotic-gastrointestinal-treatments-63154.html